283 related articles for article (PubMed ID: 16337943)
1. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.
Bankiewicz KS; Daadi M; Pivirotto P; Bringas J; Sanftner L; Cunningham J; Forsayeth JR; Eberling JL
Exp Neurol; 2006 Feb; 197(2):363-72. PubMed ID: 16337943
[TBL] [Abstract][Full Text] [Related]
2. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
3. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
4. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Bankiewicz KS; Eberling JL; Kohutnicka M; Jagust W; Pivirotto P; Bringas J; Cunningham J; Budinger TF; Harvey-White J
Exp Neurol; 2000 Jul; 164(1):2-14. PubMed ID: 10877910
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus-mediated gene transfer of human aromatic L-amino acid decarboxylase protects mixed striatal primary cultures from L-DOPA toxicity.
Doroudchi MM; Liauw J; Heaton K; Zhen Z; Forsayeth JR
J Neurochem; 2005 May; 93(3):634-40. PubMed ID: 15836622
[TBL] [Abstract][Full Text] [Related]
6. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
7. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
[TBL] [Abstract][Full Text] [Related]
8. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
Vinuela A; Hallett PJ; Reske-Nielsen C; Patterson M; Sotnikova TD; Caron MG; Gainetdinov RR; Isacson O
Brain; 2008 Dec; 131(Pt 12):3361-79. PubMed ID: 18988638
[TBL] [Abstract][Full Text] [Related]
9. Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Lieu CA; Deogaonkar M; Bakay RA; Subramanian T
Parkinsonism Relat Disord; 2011 Jan; 17(1):34-9. PubMed ID: 21074478
[TBL] [Abstract][Full Text] [Related]
10. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
11. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
[TBL] [Abstract][Full Text] [Related]
12. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
[TBL] [Abstract][Full Text] [Related]
13. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
[TBL] [Abstract][Full Text] [Related]
14. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
[TBL] [Abstract][Full Text] [Related]
15. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
[TBL] [Abstract][Full Text] [Related]
16. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Sánchez-Pernaute R; Harvey-White J; Cunningham J; Bankiewicz KS
Mol Ther; 2001 Oct; 4(4):324-30. PubMed ID: 11592835
[TBL] [Abstract][Full Text] [Related]
17. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.
Forsayeth JR; Eberling JL; Sanftner LM; Zhen Z; Pivirotto P; Bringas J; Cunningham J; Bankiewicz KS
Mol Ther; 2006 Oct; 14(4):571-7. PubMed ID: 16781894
[TBL] [Abstract][Full Text] [Related]
18. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
19. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
Bourque M; Grégoire L; Di Paolo T
Behav Brain Res; 2018 Jan; 337():183-185. PubMed ID: 28917506
[TBL] [Abstract][Full Text] [Related]
20. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Schneider JS
Pharmacol Biochem Behav; 1989 Sep; 34(1):193-6. PubMed ID: 2576311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]